Replies to post #9705 on Biotech Values

[urche]

Any comments on the GTCB PR?

My response is similar to yours, DEW.
The trial design details seem to be everything we could have asked for. For a second I was concerned that enrollment would take a year, but then I realized that in 25 yrs of medical practice I have yet to encounter a creature in whom I was aware of the anti-thrombin deficiency diagnosis. So, it may take that long to not only find the creatures, but wait for them to have a high-risk procedure or pregnancy.

Of course I am disappointed that the EMEA discussions are going to last into June. But, it was wishful thinking for a quicker resolution.

Urche

[biocrio]

*If GTCB can only convince the Europeans to approve ATryn, some very nice returns are possible for shareholders*

That, unfortunately is a very big 'if'. Good luck---biocrio